To include your compound in the COVID-19 Resource Center, submit it here.

Spero closes $30M series B round

Anti-infective play Spero Therapeutics LLC (Cambridge, Mass.) secured $30 million in a tranched series

Read the full 140 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE